Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.43 |
| ▸ | RBP4 | P02753 | 2/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.36 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18795007 | 0.86 | BTK (0.41) | BTKRBP4KLKB1GRIN2BSMPD3 | |
| SCHEMBL23769144 | 0.78 | SMPD3 (0.38) | RBP4KLKB1SMPD3PDE10A | |
| SCHEMBL21713053 | 0.78 | KLKB1 (0.45) | KLKB1SMPD3 | |
| SCHEMBL23769147 | 0.78 | SMPD3 (0.38) | RBP4KLKB1SMPD3PDE10A | |
| SCHEMBL23769616 | 0.75 | SMPD3 (0.36) | RBP4KLKB1GRIN2BSMPD3PDE10A | |
| SCHEMBL23769659 | 0.74 | SMPD3 (0.35) | KLKB1SMPD3PDE10A | |
| SCHEMBL23768886 | 0.73 | SMPD3 (0.35) | RBP4KLKB1SMPD3PDE10A | |
| SCHEMBL18815297 | 0.71 | BTK (0.58) | BTKKLKB1 | |
| SCHEMBL18816600 | 0.71 | BTK (0.58) | BTKKLKB1 | |
| SCHEMBL23769165 | 0.70 | BTK (0.44) | BTKRBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3368524-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3368524-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| US-10640486-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| US-10640486-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| US-20180319771-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-08 | — | — | US | disclosed |
| EP-3368524-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017072021-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017072021-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640486-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | BTK 3335/4885RBP4 1196/4885KLKB1 1/4885 |
| US-20180319771-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | BTK 3335/4885RBP4 1196/4885KLKB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.